|This Slide: #76 of 100|
Slide #76. MEI Pharma, Inc. — PWT143
MEI Pharma, Inc. (NASDAQ:MEIP)
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has acquired exclusive worldwide rights to the investigational drug candidate PWT143 from Pathway Therapeutics, Inc., a privately held pharmaceutical company, for an undisclosed upfront payment with no future milestone or royalty obligations.
MEI Pharma is a late-stage pharmaceutical company focused on the development and commercialization of cancer therapies. Co.'s drug candidate pipeline includes: Zandelisib, an oral, once-daily, selective phosphatidylinositol 3-kinase delta inhibitor for the treatment of B-cell malignancies; Voruciclib, an orally administered cyclin-dependent kinase inhibitor; ME-344, a tumor selective, isoflavone-derived mitochondrial inhibitor drug candidate; and Pracinostat, an oral histone deacetylase inhibitor being evaluated in patients with high or very high-risk myelodysplastic syndrome who are previously untreated with hypomethylating agents.
MEIP SEC Filing Email Alerts Service
Open the MEIP Page at The Online Investor »
Free MEIP Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Strong Buy (4.00 out of 4)